CFM
NRIX icon

Catalyst Funds Management’s Nurix Therapeutics NRIX Stock Holding History

Catalyst Funds Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,800
Closed -$85.3K – 1461
2024
Q1 		$85.3K Buy
+5,800
New +$62.4K 0.02% 435

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Catalyst Funds Management's NRIX Position: Q2 2024 in Review

Catalyst Funds Management sold out of Nurix Therapeutics (NRIX) in Q2 2024, closing a stake of 5,800 shares — an estimated $85.3K sold.

Catalyst Funds Management first reported a position in NRIX in Q1 2024 and held it in 1 quarter. The position peaked at $85.3K in Q1 2024. 173 funds tracked by Wall St. Rank hold NRIX as of Q2 2024.

  • Catalyst Funds Management reported no remaining Nurix Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 5,800 Nurix Therapeutics shares in Q2 2024, an estimated $85.3K.
  • Catalyst Funds Management first reported a position in Nurix Therapeutics in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Nurix Therapeutics position peaked at $85.3K in Q1 2024.
  • 173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.